Investor Presentation March, 2015

Introduction Executive Team Virginia Long- President AMS Mid America Dialysis Renal Care Group Christopher Pyrek – SVP Business Development Renal Care Partners, Vivra Renal Care, Health Care Properties & Development. John Ales– VP Business Development USRC, Renal Care Partners., National Renal Group John Johnson, – Executive Officer, Clinical Compliance Jewish Hospital & St. Mary’s Healthcare System Stites & Harbison Humana Inc. PROPRIETARY AND CONFIDENTIAL

The Company Capital Raise Raise $5 Million: Debt+Equity. Use of Proceeds: Equity to develop denovo clinics. Debt availability for acquisitions. Working Capital. Fees & Expenses. Provides funding for growth through 2020. PROPRIETARY AND CONFIDENTIAL

The Company History and Current Status Founded January 5, 2014. Primary Funding to Date: $.8 Million in Common Stock Units – September 2014. Current Status as of March 1, 2015: 3 De-novo deals executed. 1 acute care program in operation PROPRIETARY AND CONFIDENTIAL

Industry Overview The ESRD Market End Stage Renal Disease Population: 615,899 patients in 2011; growing at 4.3%. Total ESRD spending = $49.3. Billion in 2013. $34.4 Billion Federal Government (Medicare). $14.9 Billion Private Pay Sources. Dialysis Treatment In 2005, 70.3% of ESRD Population (341,000 patients). USRDS 2020 Projection: 786,000 patients 92.4% Hemodialysis/7.6% Peritoneal Dialysis. 6o%+ of patients are served by two major providers (FMS and DVA). PROPRIETARY AND CONFIDENTIAL

Industry Overview The Dialysis Population 2011: 615,899 Dialysis Patients 2020: USRDS Projection = 786,000 Patients Incident & Prevalent Dialysis Patient Counts/Transplant Event Counts PROPRIETARY AND CONFIDENTIAL

Industry Overview Growth Opportunity ESRD/Dialysis Population Growth necessitates clinical expansion. Dialysis population growth of 18,000-20,000 patients/year. 300-400 new clinics/year. Major public players prefer buy versus build. PROPRIETARY AND CONFIDENTIAL

The Company New Development Opportunities Clinical Cluster Expansion Florida Virginia Georgia New Cluster Markets Michigan New Clinical Development Home Program Growth Acute Care Program Growth Virginia Florida Home Care Acute Care New Clusters/ Clinics Georgia PROPRIETARY AND CONFIDENTIAL

The Company Growth Strategy Multiple opportunities for new clinical development. Growing patient population. Target certain growth and services areas: Expiration of agreements. Dissatisfaction with big chains. Growing patient base. Ownership opportunity. Trend toward nephrology groups. Facility Clusters in Geographic Regions. Maximize management efficiency. Create significant local market share for physician awareness. Obtain provider contracts. Create greater value. PROPRIETARY AND CONFIDENTIAL

The Company Growth Strategy-Home Home Growth – Primary Focus - Developing market though Physician Partnerships via Joint Ventures. - NCG ownership: 51% or more of the center. - Increased revenue vs lower costs. - Less initial investment - CKD clinics, training centers - Pathway to larger centers PROPRIETARY AND CONFIDENTIAL

The Company Growth Strategy- Chronic DeNovo Growth – Primary Focus - Physician Partnerships via Joint Ventures. - NCG ownership: 51% or more of the clinic. - Facility Clusters. PROPRIETARY AND CONFIDENTIAL

The Company Growth Strategy Acquisition Based Growth – Secondary Focus - Single or multiple clinic acquisitions in areas with strong potential for future de novo development. - Structure: Prefer Cash/Stock combination. - EBITDA multiples 4x-6x. PROPRIETARY AND CONFIDENTIAL

The Company Growth Strategy – Ancillary Focus - Physician Practice acquisition and development. - Vascular Access Centers PROPRIETARY AND CONFIDENTIAL

The Company Revenue Model Assumptions Revenue Per Patient: $270/Treatment. 3 Treatments/Week. 12 Treatments/Month. 144 Treatments/Year. $39,000/Patient/Year. Medicare 85% Private 5-10% PROPRIETARY AND CONFIDENTIAL

PROPRIETARY AND CONFIDENTIAL The Company Development Status- Currently signed Clinic # Stations Patient Capacity Opening Date Chantilly, VA _ UL Q2 2015 Bethlehem, GA 4 24+ Eufala, AL 24 + Q3 2015 Eufala,AL Inpatient Q1 2015 PROPRIETARY AND CONFIDENTIAL

PROPRIETARY AND CONFIDENTIAL

The Company Business Development Pipeline PROPRIETARY AND CONFIDENTIAL

Conclusion Liquidity Goals, Alternatives and Timing Objectives Alternatives Acquisition Merger Public Offering Timing PROPRIETARY AND CONFIDENTIAL

Conclusion Acquisition Multiples and Criteria Strategic Acquisition Multiples - 8x - 12x Clinical Contribution Margin (Clinical EBITDA before Corporate Overhead). Valuation Considerations Scale: # Patients / # Clinics. Strategic Fit: Geography, Clustering, Payors. Payor Mix. PROPRIETARY AND CONFIDENTIAL

Conclusion Significant Market Transactions Third Quarter 2013 USRC Acquires Innovative Dialysis Third Quarter 2011 Innovative Dialysis Acquires Renal Care Partners Fresenius Acquires Liberty Dialysis Fourth Quarter 2010 Liberty Acquires Renal Advantage. Fourth Quarter 2008 Renal Advantage Acquires National Renal Alliance Opportunities Exist : Only one other new company formation to fill the gap PROPRIETARY AND CONFIDENTIAL